What Pharmasyntez does

Pharmasyntez (Фармасинтез) is a privately held Russian biopharmaceutical group founded in 1997, operating seven GMP-certified manufacturing sites across Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow (Zelenograd), with more than 6,000 employees. The group runs a vertically integrated full-cycle production model spanning API synthesis (BratskKhimSintez, 250 tonnes/year capacity by 2025), Blow-Fill-Seal infusion solutions (IST-Pharm, Ussuriysk), hormonal drugs at Europe's largest such plant (Pharmasyntez-Tyumen, 500,000 packs/month), fill-finish and lyophilization for oncology cytostatics (Pharmasyntez-Nord, 45 trade names), recombinant long-acting insulin, monoclonal antibodies, and oligonucleotide APIs. Its portfolio targets tuberculosis, HIV/AIDS, oncology, diabetes, hormonal disorders, and chronic renal failure dialysis, with proprietary brands Perylazone (anti-TB, 77 countries), Serogard (anti-adhesion, 140 countries, Phase III), and Kalivid (HIV, 49 countries), backed by 38 Russian/Eurasian patents and 211 international patents.

The core revenue model is Russian federal and regional public procurement for the Vital and Essential Medicines List (ZHNVLP), where domestic API synthesis earns 30-40 procurement points versus 10-15 for secondary packaging. A secondary revenue stream comes from direct government-to-government exports to ministries of health in Syria, Afghanistan, Libya, Belarus, Myanmar, and Brazil, supported by GMP certifications from ANVISA (Brazil), Libya, and Syria. A third stream is medical devices for hemodialysis and peritoneal dialysis produced by Pharmasyntez-Medtech (Kaluga), addressing Russia's 59,000+ dialysis patients currently served by imports.

Strategic posture is anchored to Russia's Pharma 2030 import substitution mandate (90% domestic production of essential medicines target), with aggressive capital deployment of more than 60 billion rubles across Phase 3 St. Petersburg biotechnology (30 billion rubles), Pharmasyntez-Medtech Kaluga (20 billion rubles by 2028), Bratsk Phase 3 (2 billion rubles), Tyumen Phase 2 (4 billion rubles), and a 2 billion ruble China-Russia API joint venture with Zhejiang Hengkan (Hengvey Sintez). Recent moves include a strategic alliance with Cuba's CNEURO for Alzheimer's drug development, Belarus cooperation with Belpharmprom, and a Rospotrebnadzor Category 4 pathogen license enabling in-house viral safety testing for biopharmaceutical products.

Name

Pharmasyntez

Legal name

Акционерное общество «Фармасинтез»

Website

https://pharmasyntez.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Privately held Russian biopharmaceutical group operating seven GMP-certified manufacturing sites, producing full-cycle generic and proprietary drugs (TB, HIV, oncology, diabetes, hormonal) plus dialysis medical devices for Russian public procurement and government-to-government export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Biopharmaceutical manufacturing
• Oncology drug production
• Hormonal medications

Headquarters

HQ city

Irkutsk

HQ country

Russia

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations

Revenue model

1. Pharmaceutical Product Sales (Domestic Russia): Sale of pharmaceutical products through public procurement tenders to Russian federal and regional healthcare systems. Products include oncology drugs, anti-tuberculosis, antiretroviral, hormonal, diabetes, dialysis, and输液 medications. The majority of products are on the Vital and Essential Medicines list (ZHNVLP).
2. International Pharmaceutical Exports: Direct supply agreements with foreign governments and ministries of health for pharmaceutical products. Export destinations include Syria, Afghanistan, Libya, North Africa, Belarus, Myanmar, Brazil. GMP certifications obtained for multiple international markets.
3. Medical Devices (Pharmasyntez-Medtech): Production and sale of medical devices including consumables for hemodialysis, peritoneal dialysis equipment and consumables, dialyzers for treatment of chronic renal failure.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Pharmasyntez is a vertically integrated Russian biopharmaceutical manufacturer operating full-cycle production from active pharmaceutical ingredient (API) synthesis to finished dosage forms. The group produces generic and innovative medicines across tuberculosis, HIV/AIDS, oncology, diabetes, hormonal, and dialysis therapeutic areas through seven manufacturing sites in Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow).

Product overview

Pharmasyntez Group is one of Russia's leading biopharmaceutical companies, operating as a multi-site manufacturing conglomerate with seven production facilities across Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow). The portfolio is organized around therapeutic areas — oncology, tuberculosis, HIV/AIDS, diabetes, and hormonal disorders — and includes both proprietary innovative drugs and generic/biosimilar products. Key innovative brands include Pakhlozon (tuberculosis, patented in 77 countries), Serogard (anti-adhesion, Phase III), Kalidavir (HIV), Saterex (diabetes, Russia's only domestically produced formulation), and Ziflukort (fludrocortisone). Core generic portfolios span cytotoxic oncology drugs (45 trade names at Pharmasyntez-Nord), hormonal preparations (24 trade names at Pharmasyntez-Tyumen), infusion solutions via Blow-Fill-Seal (IST-Pharm, Ussuriysk), and active pharmaceutical substances (APIs) for anti-tuberculosis, antiretroviral, and anti-oncology drugs (Bratskkhimsintez). Pharmasyntez-Medtech (Kaluga) extends the group into medical devices for dialysis. Pipeline includes an Alzheimer's therapy with Cuba's CNEURO and multiple international export expansions.

Differentiator

Problem solved

Functional benefit

Brands

• Перхлозон® (Perchlazone®): Anti-tuberculosis drug (TUreoidoiminomethylpyridinium perchlorate) for treating pulmonary tuberculosis including multi-drug resistant forms, patented in 77 countries
• Серогард® (Serogard®)
• Калидавир® (Kalidavir®)
• Сатерекс (Satyereks)
• Зифлукорт (Ziflukort)
• Протуб-4®
• Протуб-2®

Products and services

• Pakhlozon (Перхлозон)

Quantifiable outcome

• Pharmasyntez-Nord captured nearly 100% of domestic semaglutide market within 12 months of compulsory license (extrapolated from market data)
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Twelve partnerships are on record, tiered minor and core.

• RWB Zdorovye (RWB Health)minorStrategic or Co-development Partner · 5 June 2026Memorandum of cooperation signed between Pharmasyntez Group and RWB Zdorovye for joint projects in women's health and reproductive medicine, and development of healthcare sovereignty solutions for Russia. Companies agreed to jointly develop a platform combining patient support tools, digital services, and education on women's health, reproductive medicine, and prevention of endocrine and metabolic disorders.
• Government of St. PetersburgcoreOthers · 5 June 2026Pharmasyntez-Nord and the Government of St. Petersburg signed investment agreement for third phase of biotechnological production complex. Government provides consulting, informational support, and assistance with negotiations and joint events. Pharmasyntez-Nord invests 30 billion rubles creating 1,000+ jobs. Signed in presence of Minister of Industry and Trade Anton Alikhanov and Governor Alexander Beglov.
• Zhejiang Hengkan Pharmaceutical (Чжэцзян Хэнкан Фармасьютикал)coreStrategic or Co-development Partner · 3 June 2026BratskKhimSintez (part of Pharmasyntez Group) and Chinese Zhejiang Hengkan Pharmaceutical signed an agreement to create a joint venture named Hengvey Sintez for development and synthesis of active pharmaceutical substances. Investment exceeds 2 billion rubles. First production complex planned in Bratsk, Irkutsk Oblast. The joint venture will focus on APIs for drugs treating socially significant diseases, strengthening pharmaceutical sovereignty of Russia.
• Government of Irkutsk OblastcoreOthers · 3 June 2026Governor Igor Kobzev and Pharmasyntez President Vikram Punya signed additional agreement to existing social-economic cooperation contract at St. Petersburg Economic Forum. Document fixes tax contributions to regional budget for 2026-2027 and list of social initiatives supported by the company. Pharmasyntez is one of the largest taxpayers and reliable social partner in the Irkutsk region.
• Afghanistan Ministry of HealthminorOthers · 27 May 2026Pharmasyntez Group agreed with Afghan Ministry of Health to begin supplies of pharmaceutical products to Afghanistan. First batches planned for delivery within two months. This expands export geography and international presence of the Russian manufacturer.
• Cuban Center for Neuroscience CNEURO (BioCubaFarma)coreStrategic or Co-development Partner · 11 February 2026Pharmasyntez Group and Cuban Center for Neuroscience CNEURO (part of BioCubaFarma conglomerate) announced start of a joint project to create a new drug for treatment of Alzheimer's disease. This represents a strategic alliance combining Pharmasyntez's manufacturing capabilities with CNEURO's neuroscience research expertise.
• Government of Tyumen OblastminorOthers · 2 June 2025Pharmasyntez and Tyumen Oblast Government signed cooperation agreement for development of regional culture. Governor Alexander Moor and Pharmasyntez President Vikram Punya signed the document. Partnership includes joint cultural initiatives and Tyumen Philharmonic's international performances including in China.
• Belpharmprom (Belarusian Pharmaceutical Industry Holding)coreStrategic or Co-development Partner · 27 May 2025Memorandum of understanding signed between Pharmasyntez and Belpharmprom to develop strategic cooperation in pharmaceutical industry, joint implementation of innovative solutions, and strengthening of partnership ties. Pharmasyntez has two strategic production projects in Tyumen Oblast for hypoglycemic and hormonal drugs. Negotiations conducted with Belpharmprom subsidiaries including RUP Belmedpreparaty, OAO BZMP, and OAO Nesvizhsky Zavod Meditsinskikh Preparatov.
• Libya Ministry of HealthminorOthers · 23 March 2025Pharmasyntez and Pharmasyntez-Tyumen passed GMP inspection by Libyan Ministry of Health in December 2024; certificate received March 12, 2025. This opens the way for supplies of high-quality medications to Libya. Pharmasyntez-Tyumen is the largest hormonal drug manufacturing plant in Europe.
• ANVISA (Brazilian Health Regulatory Agency)minorOthers · 28 December 2024Pharmasyntez-Nord became the first Russian company to receive ANVISA GMP certification for finished dosage form manufacturing in Brazil — a historic achievement for the Russian pharmaceutical industry in South America. Plans to begin drug registration process in Brazil in Q1 2025 and expand presence across the LATAM region.
• Bratsk City AdministrationminorOthers · 10 December 2024BratskKhimSintez and Bratsk city administration signed social-economic partnership agreement. Mayor Alexander Dubrovin and General Director Ivan Dratsky signed the agreement. BratskKhimSintez will finance various city-initiated projects in the coming year, supporting local social and infrastructure development.
• Syrian Ministry of HealthminorOthers · 1 March 2024Pharmasyntez became one of the first Russian companies to supply oncology medications to Syria. GMP inspection passed in July 2023; company registered in Syria in March 2024. Production capacity allows full coverage of Syria's needs for socially significant medicines.

Scale indicators17 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• BIOCAD: Russian biotech company developing and manufacturing biosimilars, monoclonal antibodies, and innovative biologics. Directly comparable as a domestic manufacturer competing on similar import-substitution themes in oncology and autoimmune diseases.
• Valenta Pharm: Russian pharmaceutical manufacturer producing branded generic and original drugs across therapeutic areas. Comparable in scale, domestic-market focus, and product portfolio breadth serving the same Russian government channels.
• R-Pharm: Russian pharmaceutical manufacturer with portfolio spanning oncology, anti-infectives, and hospital products. Comparable therapeutic mix, GxP-certified domestic production, and similar reliance on Russian public procurement and import substitution.
• Polysan: Russian pharmaceutical manufacturer with focus on generics, anti-infectives, and hospital products. Comparable domestic manufacturer serving Russian federal procurement with similar therapeutic mix.
• Sotex: Russian pharmaceutical manufacturer producing generic and specialty drugs, including oncology and hospital injectables. Directly comparable finished-dose generic manufacturer with similar customer base and distribution channels.
• Generium: Russian biotech firm focused on biosimilars, orphan drugs, and blood products. Closely comparable biologics/biosimilars portfolio and domestic manufacturing footprint serving the same Russian healthcare customer base.

Emerging players

• NovaMedika: Russian pharmaceutical and biotech company focused on generics and biosimilars including insulin products. Comparable as a domestic biosimilar/generics player overlapping in diabetes and chronic disease therapy areas.

Regional players

• KRKA: Slovenian-based generic pharmaceutical manufacturer with strong presence across CEE/CIS markets including Russia. Comparable as a generics-heavy multi-site producer targeting similar Eastern European and CIS customers.
• Gedeon Richter: Hungarian-headquartered pharmaceutical company with generics, biosimilars, and women's health portfolio and historic strength in CEE/CIS. Comparable in generics manufacturing scale and regional market orientation.

Broad incumbents

• Pharmstandard: Largest Russian pharmaceutical company by sales, with broad generics and consumer health portfolio. Comparable as a leading Russian pharma but materially larger and more diversified across OTC, consumer health, and Rx categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmasyntez